Organizer
SelectScience
SelectScience
SelectScience® is an innovative online publisher within the science industry, connecting scientists to information to help them make the best choices for their lab, through a combination of rich content, peer-to-peer information & trusted product reviews.
Tags
Sample prep
LinkedIn Logo

Critical antimicrobial susceptibility testing results for critical patients: A 2025 perspective

RECORD | Already taken place Tu, 17.3.2026
Learn how accurate MIC-based antimicrobial susceptibility testing supports faster therapeutic decisions, improves outcomes for critically ill patients, and strengthens antimicrobial stewardship programs.
Go to the webinar
SelectScience: Critical antimicrobial susceptibility testing results for critical patients: A 2025 perspective
SelectScience: Critical antimicrobial susceptibility testing results for critical patients: A 2025 perspective

The microbiology laboratory plays a vital role in selecting antimicrobial susceptibility testing (AST) methods to guide treatment of severe infections in critically ill patients. Delayed or inaccurate results, especially in multi-drug-resistant cases, can lead to poor outcomes and higher mortality.

In this SelectScience webinar Dr. James A. McKinnell, M.D. an infectious disease specialist, will describe how accurate minimum inhibitory concentration (MIC) data can improve turnaround times, optimize therapeutic decisions, and support the use of new treatments. The session will explore how reliable broth microdilution-based MICs for novel antibiotics enhance patient outcomes while reducing length of stay, adverse effects, and costs.

Join the webinar to learn how antimicrobial stewardship efforts are most effective when supported by timely diagnostics and collaboration among microbiologists, clinicians, stewardship teams, and policymakers, helping to address the global challenge of antibiotic resistance in the post-Covid era.

Key learning objectives:

  • Describe the role of the microbiology laboratory in guiding AST for critically ill patients.
  • Recognize the value of accurate MIC data in improving turnaround times, optimizing therapy, and supporting new antibiotic use.
  • Identify how antimicrobial stewardship programs rely on timely diagnostic data and collaboration to improve patient outcomes.
  • Discuss the importance of multidisciplinary collaboration among microbiologists, clinicians, stewardship teams, and policymakers to combat antibiotic resistance in a post-Covid world.

Who should attend?

  • Clinical microbiologists, laboratory technicians, lab managers, lab directors, infectious disease specialists, and infectious disease clinicians.

Accreditation statement

SelectScience® is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E.® Program. Attendees of these webinars may be entitled to 1.0 ACCENT Continuing Education Credits from the ADLM. This activity was planned in accordance with ACCENT® Standards and Policies. Verification of Participation certificates are provided to registered participants based on completion of the activity, in its entirety, and the activity evaluation. For questions regarding continuing education, please email [email protected].

Presenter: Dr. James A. McKinnell (M.D. and Infectious Disease Specialist, Milefchik-Rand Medical Group, Torrance and Memorial Medical Center, Torrance CA)

Dr. James A. McKinnell is an infectious disease specialist whose research focuses on healthcare-associated infections, particularly VRE, MRSA, and carbapenem-resistant organisms. He has authored over 40 publications on antibiotic optimization and antimicrobial resistance. Dr. McKinnell works closely with skilled nursing facilities in Los Angeles and Orange County (USA) to develop practical infection prevention and stewardship strategies. He also contributes as an invited speaker for the Infectious Disease Association of California and as a committee member for Los Angeles County’s HAI and antimicrobial resistance initiatives.

Moderator: Sarah Thomas (Associate Editor, SelectScience)

SelectScience
LinkedIn Logo
 

Related content

Simultaneous Quantitation and Discovery analysis: Combining targeted and untargeted metabolomics on Orbitrap mass spectrometers

Applications
| 2026 | Thermo Fisher Scientific
Instrumentation
LC/MS, LC/MS/MS, LC/Orbitrap, LC/HRMS
Manufacturer
Thermo Fisher Scientific
Industries
Metabolomics

Analysis of Per- and Polyfluoroalkyl Substances (PFAS) in Wastewater

Applications
| 2026 | Agilent Technologies
Instrumentation
LC/MS, LC/MS/MS, LC/QQQ
Manufacturer
Agilent Technologies
Industries
Environmental

Non-Targeted Screening of Biosolids with the Xevo™ MRT Mass Spectrometer Reveals New Isoforms of PFAS

Applications
| 2026 | Waters
Instrumentation
LC/MS, LC/MS/MS, LC/TOF, LC/HRMS
Manufacturer
Waters
Industries
Environmental

High Resolution Characterization of Lipid Nanoparticles Using the Xevo™ Charge Detection Mass Spectrometry (CDMS) Instrument - Single Particle Mass Analysis of Intact LNP-mRNA Formulations

Applications
| 2026 | Waters
Instrumentation
LC/MS, LC/MS/MS, LC/HRMS, Particle characterization, LC/IT
Manufacturer
Waters
Industries
Lipidomics

Out-of-the-box workflow for PFAS quantitation using a fullscan high-resolution approach with the Orbitrap Exploris EFOX Mass Detector

Applications
| 2025 | Thermo Fisher Scientific
Instrumentation
LC/MS, LC/MS/MS, LC/Orbitrap, LC/HRMS
Manufacturer
Thermo Fisher Scientific
Industries
Environmental
Other projects
GCMS
ICPMS
Follow us
FacebookX (Twitter)LinkedInYouTube
More information
WebinarsAbout usContact usTerms of use
LabRulez s.r.o. All rights reserved. Content available under a CC BY-SA 4.0 Attribution-ShareAlike